OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
... (pemetrexed) was well tolerated and resulted in median
progression-free survival of 3.3 months.
... grade 3 or greater nonhematologic toxicities. A median
of 4.5 cycles was delivered in each cohort.
... patients were alive at time of data presentation. median
progression free survival was 3.3 months.
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
... shrinkage (95% confidence interval: 26-41%). The median
time to disease progression for all 145 patients was 4.3 months (95% CI; 3.6-5.9 months) and the median
duration of response for the 48 responders was ... despite prior treatment. Patients had received a median
of four prior therapies (between one and 15 ...
Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
... cell (CTC) counts.
New findings include the median
time to PSA progression, which was 6.1 months for post-chemotherapy patients, with the median
time not yet reached for chemotherapy-naive patients. In addition, the median
time to radiographic progression was 6.6 months ...
CuraGen Updates CR011-vcMMAE Data at ASCO
... on expression of GPNMB in patients' tumors. The median
number of prior chemotherapy regimens for ... observed in 34 evaluable patients, and median
duration of response of 5.3 months. The median
overall progression-free survival (PFS) was 4.4 ...
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
... vincristine and prednisone) therapy. The median
prior exposure of these patients, most of whom ... median
1 68 ...
Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
... due to a new malignancy on day 6.
prior treatment regimens was two, with prior ... grade 3/4 adverse events.
Best response and median
time to progression of capecitabine + perifosine ... N CR PR ORR Wks CBR median
N(%) N(%) N(%) ...
Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
... due to a new malignancy on day 6.
prior treatment regimens was two, with prior ... grade 3/4 adverse events.
Best response and median
time to progression of capecitabine + perifosine ... CR PR ORR SD > 12 CBR median
N(%) N(%) N(%) ...
Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
... N PR SD > 12 wks CBR* median
N (%) N (%) ... with Stable Disease or Partial Response
PFS for all 46 patients was 12.5 weeks [95% CI (11.9, 19)]. The median
overall survival has not been reached with 33 of ...
New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
... OTC(R) 40 mg (20 mg X 2), did not alter the median
time it took for maximum plasma concentration of ... resulted in a nearly 45 percent reduction in the median
time to reach maximum plasma concentrations of ...
When ADDERALL XR was administered alone, the median
time to maximum plasma amphetamine concentration ...
TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
... with a mean follow-up period of 59 days and a median
follow-up of 32 days. Noting that De Oliveira et al.(1) report the median
time to CRMD infection as 14 days, and Klug et al.(2) reported a median
time to infection of 52 days, the preliminary ...
Men Treated for Localized Prostate Cancer Could Benefit From Pomegranate Juice Consumption
... active patients who remain on the study have a median
total follow-up of 56 months. These participants ... at baseline to 60 months post-treatment, with a median
PSA slope decrease of 60 percent, 0.06 to 0.024. ... PSA doubling time prolongation and the decline in median
PSA slope were greater in active patients when ...
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
... in rapid and sustained reductions in HCV RNA with median
reductions at end of treatment (Day 4) exceeding ... dose levels. At 200 mg bid (twice-daily), the median
viral load reduction was 2.4 log10 (range of 0.4 ... 2.2 to 3.4). Genotype 1a patients demonstrated median
reductions of 1.4 log10, 1.8 log10, and 2.5 log10 ...
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
... - 31% COMPLETE RESPONSE RATE
SURVIVAL OF 10.5 MONTHS IN COMPLETE RESPONDERS
... full blood count recovery (CRi). The estimated median
overall survival (OS) in responders was 10.5 ... the nine CRs were still alive at that time, the median
OS in this group may prove to be longer.
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
... 73 patients were evaluable for response. median
prior lines of therapy was 5 (range 1 - 13), ... relapsed on a bortezomib-based treatment had a median
time to progression (TTP) of 8.5 months. The median
TTP for all 73 evaluable study patients (both ...
Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
... stability, the primary endpoint, showed a median
of 23.7 hours for peramivir 200 mg, 37.0 hours ... from baseline in viral titer) was reduced by a median
of -2.0 logs for peramivir 200 mg, -2.1 logs for ... Patients were discharged from hospital after a median
of 4.0 days for peramivir 200 mg, 3.8 days for ...
Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
... and chemotherapy) without DCVax(R)-Brain
have a median
survival of only 14.6 months, and less than 5% of ... patients have lived longer than the
survival of 14.6 months with existing standard of ... progression (recurrence) for longer than the median
free survival of 6.9 months ...
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
... ongoing Phase Ib trial demonstrated a 2.5 log10 median
viral load decline after three days
... days. At the end of the treatment period, the median
viral load decline was 2.5 log10 (>99%), with ... ANA598 were genotype 1a and demonstrated a median
viral load decline of 1.6 log10, while five ...
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
... and 66 patients in the Phase II component). median
prior lines of therapy was 5 (range 1 - 13), ... to 4 cycles
TTP for all study patients was 6.3 months. median
TTP for responding patients has not yet been ...
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
... doses of Campath three times per week. After a median
follow-up time of 37.9 months, the study found an ... of 30 percent among the total patient population. median
PFS time was 7.7 months, and median
OS time was 19.1 months.
Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
... analysis was presented at ASH 2007. Data with a median
follow up of 25.9 months were presented at this ... with the MP arm (hazard ratio =0.644, p=0.0032; median
survival not yet reached in either arm).
... VcMP arm. Patients remained on VcMP therapy for a median
of 46 weeks (eight cycles) out of the planned ...
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
... dehydrogenase (LDH), decreased 86 percent from a median
1,814 U/L at baseline to a median
of 244 U/L following 12 weeks of
treatment ... treatment (P<0.001 for the pre-specified median
independence was ...
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
... chemotherapy. In Schedule A, 29 patients with a median
age of 75 were enrolled and treated with 72 ... blast reductions to less than 5 percent. The median
duration of response for patients achieving a CR ... is generally a disease of older adults and the median
age of a patient diagnosed with AML is about 67 ...
Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders
... and high-dose arms, respectively. The median
number of red blood cell transfusions (usually ... with those in the placebo arm. While baseline median
platelet counts were 16,000 microliters in both ... in the placebo group. This is in contrast to median
platelet counts rising to 36,000 microliters in ...
GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Throughout the study, the median
platelet count in the placebo group ... in the
PROMACTA arm experienced a rise in their median
platelet count to
36,000/microliters, with median
platelet levels subsequently ranging from
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
... prostate cancer. The current 10.6
overall survival advantage observed in the OGX-011 arm represents
an increase over the median
survival observed in the control arm. OGX-011 ... cancer refractory to
hormone therapy showed a median
survival of 27.5 months for the patients in
Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows
... taken daily for just under two years reduced median
LDL cholesterol to 55 mg/dL, down from a median
of 108 mg/dL, and median
hs-CRP (high-sensitivity C-reactive protein), a ...
New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study
... enrolled in SONIC were male and patients had a median
weight of 70 kg, median
disease duration of 2.3 ...
RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
... unknown response. Responses
were maintained for a median
of 10.6 months (8.3-N/A). Further, the results
demonstrate PFS of 9.3 months. median
overall survival had not been reached
at the time ... the results demonstrate PFS of 12.9
overall survival had not been reached at the time ...
Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain
... surviving as long as 8 years to
date. The median
survival in the patients from these trials is now ... defining this standard of care achieved a median
progression of 6.9 months and a median
overall survival of 14.6 months
(Stupp, et. al., ...
New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients
... (3,494 patients) or placebo (3,481
age of study participants was 67 years and 42 ... reasons.
Patients were followed for a median
of 3.9 years. Results from the
study showed that ... LOVAZA also resulted in an
increase in LDL-C by a median
of 45%, from ...
BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
needed. In BRIDION clinical studies, the median
time to reversal of
rocuronium was about three ... reversal regimen.
In the SIGNAL trial, the median
time to reversal of muscle relaxation to ... plus glycopyrrolate. In the AURORA trial,
time to reversal of muscle relaxation to a TOF ...
CryoCath Arctic Front(R) Results Published in JACC
... only one procedure with Arctic Front upon a median
follow-up time of
"As we continue to ... applicability of
Arctic Front cryoablation. The median
number of applications per vein was
2.8 and the median
total procedure time was 170 minutes confirming ...
BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
... chemotherapy - median
survival increase of 6.5 months seen for patients ... patients in the chemotherapy only group. The median
time for all non-small cell lung cancer ... participating in the Japan Tavocept
Trial, the median
survival time observed for patients receiving ...
Study Shows Use of AdvanDx's PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream Infections
... group vs. 56% for UC group
-- 67% reduction in median
antibiotic use after notification of
of 1 day for NPF group vs. 3 days for UC group
-- 100% reduction in median
antibiotic use for CoNS patients ...
Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
... of partial responses and an apparent increase in median
median overall survival (OS) relative to ... rate was 75%. The
median PFS was 6.4 months. The median
overall survival (OS) was 21.1
months, and the 1 ... RCC is metastatic, it is difficult to treat, and median
is between one and two years. A number ...
Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
... that Leukine(R) (sargramostim) demonstrated a median
survival of 65 months and increased ... cell analysis. Results showed that the median
was 65 months (95 percent, CI 43-67 months). median
survival was 5.6 months (95 ...
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
... (FAB) Group criteria.
age of the patients in the subset was 71 years ... of the 10 responders received
consolidation. The median
(range) of overall survival for the entire
patient group was 3.4 months (0.6-28.6) and the median
(range) of overall
survival for responders was ...
Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma
... with a 64 percent complete response
rate and a median
time to progression of 14 months. Adverse events ... whole brain
radiation therapy (WBRT) improved the median
time to neurologic progression
from 10.0 months ... alone produces a 15% complete response
rate with median
time to tumor progression of about seven months ...
Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
... defined progressive
disease (4.4 years). The median
OS for patients treated with ipilimumab ... with data in medical literature, in which median
OS ranges from 6
to 9 months for patients with ... was 21.6%, or 8 of the 37 patients, with median
OS of 12 months.
Ipilimumab is being developed ...
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
... a statistically significant
improvement in median
progression-free survival (PFS), compared ... is the only renal
cancer therapy proven to extend median
overall survival compared with
interferon-alpha ... objective response rate and
PFS for patients treated with TORISEL 175 mg/75 ...